BYND Cannasoft Announces Successful Completion of Laboratory Testing Phase for EZ-G Device Optimization

BYND Cannasoft Enterprises announced the successful completion of the laboratory testing phase aimed at optimizing the various sensors in its innovative EZ-G device. The EZ-G device, a therapeutic solution utilizing AI and machine learning, has shown promise in releasing low concentrations of CBD oils, including seed oil and other natural oils, to potentially address specific women’s health issues.

Recommended: AiThority Interview with Gregor Stühler, Co-Founder and CEO at Scoutbee

Throughout the laboratory testing phase, the Company conducted comprehensive experiments as part of the prototype development of the EZ-G device. The focus was on assessing the functionality and performance of the assembled sensors within the device, capable of detecting indicators such as temperature, heart rate, contractions, and fluids. By collecting and transferring data to the accompanying software, the information derived from these indicators was processed to optimize the device’s usage for the user through machine learning technology.

This crucial milestone in the EZ-G device’s development demonstrates the successful functionality of its capacitive sensor, the primary sensor within the device. The sensor has proven its capability to accurately detect the presence or absence of liquid within the device, specifically identifying changes in the fluid volume within the vagina. Consequently, the device can regulate the flow of oil or lubricating fluid during operation without requiring manual intervention from the user.

With the positive outcomes achieved during the trial, BYND Cannasoft is now committed to finalizing the EZ-G prototype model and progressing to the next phase of development: human trials involving focus groups of women of different age groups.

Recommended: AiThority Interview with Manuvir Das, VP, Enterprise Computing at NVIDIA

“We are thrilled with the successful completion of the laboratory testing phase for the EZ-G device,” said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft. “This accomplishment validates our dedication to harnessing advanced technology to improve women’s health. We are excited to move forward with human trials, as we believe the EZ-G device has the potential to revolutionize therapeutic approaches for women’s health issues.”

The Company remains committed to ensuring the EZ-G device meets the highest safety, efficacy, and usability standards. Through continued research and development efforts, BYND Cannasoft aims to contribute to the well-being of women by providing an innovative solution for targeted health concerns.

Recommended: AiThority Interview with Shafqat Islam, Chief Marketing Officer at Optimizely

[To share your insights with us, please write to sghosh@martechseries.com]